Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)

被引：0
|
作者：
Jain, Nitin [1 ]
Thompson, Philip [1 ]
Burger, Jan A. [1 ]
Borthakur, Gautam [1 ]
Bose, Prithviraj [1 ]
Estrov, Zeev [1 ]
Ferrajoli, Alessandra [1 ]
Gandhi, Varsha [1 ]
Plunkett, William [1 ]
Lopez, Wanda [1 ]
Kantarjian, Hagop [1 ]
O'Brien, Susan [2 ]
Keating, Michael [1 ]
Wierda, William [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, NJ USA
[3] Univ Texas, Houston, TX USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
164
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [31] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, J.
    Cramer, P.
    Bahlo, J.
    Engelke, A.
    Langerbeins, P.
    Fink, A. -M.
    Klaproth, H.
    Tausch, E.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Boettcher, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 117 - 118
  • [32] Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL)
    Hornberger, J. C.
    Reyes, C. M.
    Shewade, A.
    Friedmann, M.
    Chan, L.
    Gutierrez, H.
    Satram-Hoang, S.
    Lerner, S.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype
    Stephens, Deborah M.
    Stark, Amy
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Maddocks, Kami
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    Flynn, Joseph M. M.
    Grever, Michael R.
    Lozanski, Gerard
    Johnson, Amy J.
    Muthusamy, Natarajan
    Heerema, Nyla A.
    Byrd, John C.
    BLOOD, 2013, 122 (21)
  • [34] CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group
    von Tresckow, J.
    Cramer, P.
    Bahlo, J.
    Engelke, A.
    Langerbeins, P.
    Fink, A. -M
    Klaproth, H.
    Tausch, E.
    Fischer, K.
    Wendtner, C-M
    Kreuzer, K. -A
    Stilgenbauer, S.
    Boettcher, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 121 - 121
  • [35] POTENTIAL LONG-TERM COST SAVINGS DUE TO SIGNIFICANT CLINICAL BENEFIT OF OBINUTUZUMAB (GA101) IN COMBINATION WITH CHLORAMBUCIL IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Walzer, S.
    Tournier, C.
    Marino, J. P.
    Mueller, E.
    Duong, M.
    VALUE IN HEALTH, 2013, 16 (07) : A400 - A401
  • [36] PREDICTIVE CLINICAL MODEL FOR UNTREATED DEL(17P13.1) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
    Stephens, D.
    Ruppert, A.
    Jones, J.
    Woyach, J.
    Maddocks, K.
    Jaglowski, S.
    Andritsos, L.
    Flynn, Joseph M.
    Grever, Michael R.
    Muthusamy, N.
    Heerema, N.
    Byrd, J.
    HAEMATOLOGICA, 2013, 98 : 39 - 39
  • [37] A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)
    Mulligan, Stephen
    Tam, Constantine
    Badoux, Xavier
    Kuss, Bryone
    LEUKEMIA & LYMPHOMA, 2015, 56 : 25 - 26
  • [38] CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
    Sharman, Jeff P.
    Laurenti, Luca
    Ferrant, Emmanuelle
    Montero, Luis Felipe Casado
    Mulligan, Stephen P.
    Harrup, Rosemary
    Opat, Stephen
    Ibatici, Adalberto
    Marasca, Roberto
    Sportoletti, Paolo
    Lefebure, Marcus
    Boyer, Michelle
    Jiang, Yanwen
    Barlera, Simona
    Cazares, Oscar
    Morschhauser, Franck
    BLOOD, 2024, 144 : 3237 - 3238
  • [39] OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY
    Visentin, A.
    Pravato, S.
    Mauro, F. R.
    Pietrasanta, D.
    Fresa, A.
    Vitale, C.
    Ciolli, S.
    Cassin, R.
    Cibien, F.
    Sportoletti, P.
    Gentile, M.
    Rigolin, G. M.
    Quaglia, F. M.
    Murru, R.
    Gozzetti, A.
    Molica, S.
    Marchetti, M.
    Scarfo, L.
    Guardalben, E.
    Avitabile, A.
    Reda, G.
    Coscia, M.
    Laurenti, L.
    Pizzolo, G.
    Semenzato, G.
    Foa, R.
    Cuneo, A.
    Trentin, L.
    HAEMATOLOGICA, 2021, 106 (10) : 62 - 63
  • [40] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGUESE PATIENTS THAT ARE UNSUITABLE FOR FULL-DOSE FLUDARABINE BASED THERAPY
    Paquete, A.
    Miguel, L. S.
    Pereira, C.
    Pinto, C. G.
    VALUE IN HEALTH, 2015, 18 (07) : A463 - A464
12345